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For over four decades structural biology has been used to understand the mechanisms
of disease, and structure-guided approaches have demonstrated clearly that they can
contribute to many aspects of early drug discovery, both computationally and experimen-
tally. Structure can also inform our understanding of impacts of mutations in human
genetic diseases and drug resistance in cancers and infectious diseases. We discuss the
ways that structural insights might be useful in both repurposing off-licence drugs and
guide the design of new molecules that might be less susceptible to drug resistance in
the future.
Structure-guided drug discovery
Ideas about the use of protein structure in drug discovery emerged in parallel with the first three-
dimensional structures defined by X-ray crystallography. An early focus on the structure of haemoglo-
bin in the 1950s stimulated thoughts about sickle cell disease in the Perutz laboratory in Cambridge
[1,2], and the structure of lysozyme in 1966 in the Phillips’ laboratory at the Royal Institution in
London described a well-defined active-site cleft, interactions with substrate and early hypotheses
about ligand binding and mechanism [3]. The structure of insulin in 1969 [4] was already a subject of
interest in the pharma industry as insulin crystals were used to treat diabetics. The many sequences of
insulin, already defined by Sanger in Cambridge, together with efforts to synthesize the protein under-
way in New York, Aachen and Shanghai, led to thoughts about design of more effective and longer-
lasting insulins for therapeutic use [5]. The availability of further sequences in the years following led
to early attempts to model human α-lactalbumin, a homologue of lysozyme found in milk [6,7], and
then later relaxin [4] and insulin-like growth factor [8], both distant homologues of insulin of interest
in biomedicine.
Although some laboratories, such as that of Dorothy Hodgkin, were well linked in to the pharma
industry, interest elsewhere in structure-guided drug discovery increased only as experimental struc-
tures of enzymes and their complexes became available in academia, often for paralogues of current
drug targets in industry. An example of this trend was renin, which had been known for many years
to be involved in regulating blood pressure through its role in processing angiotensinogen to angioten-
sin I [9]. Aspartic proteinase structures of paralogues of renin had been defined in the 1970s, and
these allowed models to be created for renin, for example, by Sibanda and colleagues [10]. These were
used in some of the earlier structure-guided drug discovery campaigns for antihypertensives. The
X-ray structures of complexes of renin inhibitors complexed with paralogues of renin appeared later
[11] and were eventually followed by high-resolution structures of renins [12,13].
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Chemical library screening strategies exploiting structure
These developments in structure-guided drug discovery occurred in parallel with an increasing interest in
target-agnostic phenotypic screening as well as roboticised screening of individual targets with chemical
libraries of increasing size. However, for drug-like molecules (optimally of molecular mass ∼500 Da), screen-
ing requires libraries much larger and more diverse than the ∼106 molecules available to most large pharma
companies. The urgent need for a more innovative approach was underlined by the exponential increase in
costs in drug discovery research and development in the 1990s, but the relatively low output of new drug
approvals. Two innovative approaches involving protein structures that have provided complementary strat-
egies have been virtual screening of very large numbers of compounds and experimental fragment-based drug
discovery.
Virtual screening explores possible binding sites in silico for a large number of small molecules [14–17],
assessing electrostatic, van der Waals or hydrogen-bonding interactions involved in molecular recognition of
candidate molecules for binding a target of known structure. Virtual screening methods (such as GOLD [18],
AUTODOCK [19] and GLIDE [20]) are used to dock large and diverse sets of drug-like molecules, in order to
identify compounds that might provide useful ‘hits’.
In contrast, fragment-based drug design is mainly an experimental approach to the challenge of moving
from hits to leads. It depends on decreasing size and complexity by exploiting a fragment library, reduced in
molecular mass (<300 Da) and in number to around a thousand molecules, which are screened against a target
of interest using biochemical, biophysical and structural methods [21,22]. The fragments are developed into
lead candidates by chemically growing or linking the fragments, thereby exploring the chemical space available
for binding to the target protein very effectively. Although low-molecular-weight fragments have relatively
lower potency than the more complex molecules found in typical high-throughput screening compound librar-
ies, small fragments that bind, do so by making well-defined and high-quality interactions and by displacing
‘unhappy’ water molecules at hotspots on the protein [23,24].
At first fragment-based drug discovery was focused on ‘druggable’ targets with large, well-defined cavities,
such as protein kinases; it was pioneered both in large companies such as Abbott, who used SAR by NMR
(structure–activity relationships by nuclear magnetic resonance (NMR) [25]), as well as in small start-ups such
as Astex, which has focused on high-throughput X-ray crystallography to screen fragments [21]. Increasingly
now fragment-based approaches involve, first, a range of biophysical methods such as surface plasmon reson-
ance (SPR) and thermal shift to screen a fragment library, and, second, others to provide a detailed analysis of
the three-dimensional structure of the fragment complex by X-ray crystallography or NMR, the thermody-
namics by isothermal calorimetry and kinetics by SPR. Molecular dynamics can also be used to explore differ-
ent conformers of the protein and even reveal cryptic sites.
Until Otsuka purchased it in 2013, Astex brought compounds into clinical trials within the company, but
also importantly developed strategic alliances with larger companies, including Jannsen, Novartis, AstraZeneca
and GlaxoSmithKline. Astex has made impressive progress in clinical trials, achieving a milestone on 1
November 2016 with US FDA’s filing of a new drug application for LEE011 (ribociclib), a drug that targets
protein kinase CDK4, which was developed in an alliance with Novartis; this will be used in combination
therapy with letrozole as a first-line treatment for advanced breast cancer.
In academia there have been attempts to use fragment-based drug discovery to target sites that have been
previously defined as ‘undruggable’, most often interfacial or allosteric sites [26]. An example of this has been
the use of fragment-based drug design to target the binding site of BRCA2-BRC repeats on Rad51, which cata-
lyses an ATP-dependent DNA strand exchange in repair by homologous recombination of DNA double-strand
breaks. This interaction involves concerted folding and binding of the BRC repeat, a foldable amino acid
sequence within intrinsically disordered regions of BRCA2, onto the globular structure of Rad51 [27]. The
BRCA2 interacts first through docking of a phenylalanine within a conserved FXXA sequence into a well-
defined pocket of Rad51. This provides an anchor for the subsequent folding as a β-turn of the BRC repeat
sequence, in order to allow the conserved alanine to bind into a smaller, more hydrophobic pocket. A further
interaction is formed by the folding as an α-helix of a C-terminal region of the repeat motif into a shallow
binding cleft. This was proposed as a possible site for targeting inhibitors and required very different chemistry
from the ‘drug-like’ molecules designed to bind classical targets like protein kinases. The small pockets are well
suited to bind fragments [28] and Cambridge labs in Biochemistry, Chemistry and Oncology have subsequently
developed nanomolar inhibitors to bind this site [29].
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Fragment-based drug discovery has also been used to develop new antimicrobials, particularly for tubercu-
losis and to target other mycobacteria. Very little work is currently developed in big pharma against pathogens
that are responsible for infectious disease in developing countries or those that cause disease to small sections
of the population, for example by Mycobacterium abscessus, which causes life-threatening lung infections in
cystic fibrosis patients [30]. Here, the fragment-based approach has the advantage of working with very small
molecules that can penetrate the cell walls. Figure 1 illustrates the binding of fragments to an essential enzyme
in Mycobacterium abscessus, a non-tuberculous Mycobacterium (Thomas, S.E., Mendes, V. and Blundell, T.L.,
unpublished data). Our screening data have shown that fragments can bind at allosteric and interfacial sites.
The allosteric sites are often not identified as functional, but occasionally even these prove to have an impact
on binding at the active site, as we have recently discovered with Mycobacterium tuberculosis CoaBC enzyme
(Mendes, V., Blaszczyk, M. and Blundell, T.L., unpublished results).
Mutations and disease
Many disease-related mutations, which are usually in residues that are conserved or conservatively varied
during evolution, have an impact on the function of proteins. Classification and better interpretation of disease
and non-disease-associated mutations is challenging but central to the understanding of genetic disease.
Structural analyses of disease-causing mutations indicate that most occur at solvent-inaccessible and hydrogen-
bonded residues [31].
Based on these observations, we proposed that the effect of a mutation on protein stability could be calcu-
lated by considering the statistical potential of a residue to change across evolution. The method site-directed
mutator (SDM) uses a set of conformationally constrained, environment-specific substitution tables, which
consider a residue’s conformation, solvent accessibility and side-chain hydrogen bonding, to calculate the
difference in stability between the wild-type and mutant protein structures [32,33]. More recently, we have used
graph-based signatures to represent the wild-type structure environment in order to predict the effect of
mutations on stability [34,35], and interactions with other proteins [35–39], nucleic acids [35], small molecules
[40–42] and metal ions [43].
These programs have provided insights into mutations that lead to a range of human genetic diseases,
including cancers. For example, von Hippel–Lindau Syndrome leads to the development of clear cell renal
Figure 1. Targeting essential enzymes in Mycobacterium abscessus: Fragment hits for PurC (SAICAR Synthetase), an
enzyme of de novo purine biosynthesis.
(A) Surface electrostatic representation of PurC in complex with ATP. (B) Fragments occupying the adenylyl pocket of PurC
making strong polar contacts. Figure prepared using PyMOL and Maestro (Schrödinger, LLC).
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carcinoma and is caused by mutations in the VHL gene (Figure 2). By considering the effect of the mutations
upon the stability of the VHL protein and how they alter the affinity for its various binding partners, HIF-1α
and Elongin B and C, we could accurately identify a patient’s risk of developing clear cell renal carcinoma
[43,44]. In subsequent studies looking at other human Mendelian diseases, we have consistently observed that
mutations affecting protein stability represent the majority of disease mutations, but those that affect key
protein–protein interactions have proved also to be common and important [45–48]. Interestingly, changes in
protein stability have even been linked to population phenotypic variability, including drug responses [49].
The same molecular consequences also drive the development of drug resistance. Looking at single-point
coding mutations in Mycobacterium tuberculosis, we observed strong correlations between the structural fea-
tures of mutations and their link to antibiotic sensitivity [51]. This suggested the possibility that we could
predict resistance mutations before they arise, allowing us to suggest optimal therapeutic interventions based on
genomic sequences and guide drug development.
We have applied this theory to our recent efforts to develop small-molecule inhibitors of GuaB2 to treat
Mycobacterium tuberculosis. Analysis of the crystal structure of GuaB2 with VCC234718 revealed the most
likely resistance mutation would occur at Y487, altering interactions with the inhibitor but not NAD, while not
disrupting protein stability or the interactions between the homo-tetramer units. Y487C was the main resist-
ance mutation observed [52]. By modifying the inhibitor, altering the interactions being made, the resistance
profile could be altered. Other molecules were identified that did not make these interactions and were active
against the Y487C mutant [53] (Figure 3). While these inhibitors were shown to be active against Mtb in vitro
through the inhibition of GuaB2, further work is needed to explore the potential therapeutic benefit of GuaB2
inhibition in vivo.
These analyses highlight the power of considering the structural environment of a mutation in order to
understand the molecular and biological consequences. While many disease mutations are buried, simple classi-
fication of residues by solvent accessibility does not provide all of the information encompassed within the
graph-based signatures, necessary to consider longer-range allosteric effects and to distinguish disease-causing
mutations. This led us to consider other structural features to locate a residue within the interior of the
structure.
Refining our understanding of the impacts of mutations on
protein function
The interiors of protein structures can be further classified using the conservation of residues in an orthologous
family, as well as the packing density and the depth of the residue. These can provide more detailed informa-
tion regarding the structural environment used in our substitution tables in SDM, allowing more accurate pre-
diction of the effects of mutation and better identification of disease-related mutations.
Figure 2. Genetic diseases mutations: clear cell renal carcinoma in von Hippel–Lindau disease.
Left-hand side panel: the structure of the ternary complex of pVHL with Elongin C and Elongin B, critical for pVHL stability and
function [50]. Right-hand side panel: Inter-subunit interactions mediated by arginine (R107). In VHL disease some mutations, for
example at R107, alter the charge complementarity of the subunits and destabilise protein–protein interactions, essential to function.
306 © 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
Biochemical Society Transactions (2017) 45 303–311
DOI: 10.1042/BST20160422
We have recently analysed the residue side-chain relative solvent accessibility (RSA) [54], packing density,
[55] and depth below the surface (http://cospi.iiserpune.ac.in/depth) [56,57] of residues across ∼15 000 high-
resolution (≤2.5 Å), representative protein structures. This demonstrated that solvent-inaccessible residues
(RSA <7%) exhibit varying levels of packing, with those closer to the core of the protein being more tightly
packed. This suggests that further categorisation<UK ise of the environment-specific substitution tables in SDM
with respect to depth and packing density might be useful in the prediction of the impact of mutations on
protein stability [32].
We have found that residue conservation progressively increases as a function of residue packing, but the
dependence on depth is more residue-specific (Figure 4; Pandurangan, A.P., work in progress). We are now
modifying the environment-specific substitution tables to reflect these observations. Both these structural fea-
tures could also add useful information while training models using machine-learning approaches to predict
the impact of mutations on protein stability and affinity.
We have also asked whether we could better identify disease-causing mutations based on residue depth,
packing density and conservation scores of the protein orthologues. To test this idea, we have investigated
mutations occurring in alkaptonuria (AKU), which was the first characterised human Mendelian disease and is
also known as black bone disease. AKU is caused by mutations in homogentisate-1,2-dioxygenase (HGD; PDB
ID: 1EY2) that lead to the accumulation of reactive metabolites. There are over 80 known single-point muta-
tions in HGD that have been linked to the development of AKU. We have previously shown that these muta-
tions affect the activity of the protein complex primarily through destabilisation of the individual protomer
structure but also through disruption of protomer–protomer interactions within the hexamer [45,46].
To visualise the relationship between residue conservation, depth and packing, we mapped the respective prop-
erties onto the structure of HGD (Figure 5). The residue conservation score was calculated using ConSurf [59]. In
AKU, about 70% of the disease mutants are highly conserved (conservation scores >7), whereas for non-disease
residues only 36% are highly conserved. Disease mutants proximal to the interface and the iron-binding site are
well conserved for the purpose of maintaining interaction and function, respectively. In general, residue conserva-
tion could act as a potential indication to distinguish between disease mutant and non-disease residues.
To better dissect the properties unique to disease mutants, we looked at the correlation between depth and
conservation for disease mutants and non-disease residues. As expected, depth was strongly correlated with
conservation for both disease mutants and non-disease residues. For disease-causing mutants, the correlation
between packing and conservation was significantly higher compared to the non-disease residues in AKU.
Residue conservations have been previously shown to be greater than expected from analysis of amino acid,
environment-dependent substitution tables in residues that are closer to functional binding sites [60], and have
been shown to be dependent on the distance of the residue from the catalytic site [60,61].
Figure 3. Avoiding resistance hotspots.
The GuaB2 inhibitor VCC234718 (represented as yellow sticks [52]) stacks on top of IMP (represented as black sticks) in a
similar manner to NAD (represented as orange sticks), but makes different interactions to the neighbouring protomer unit
through Y487, which is mutated leading to resistance. Optimisation of a separate scaffold (Compound 6, represented as purple
sticks [53]) more closely mimicked the interactions made by NAD, and was active against the Y487C mutant.
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This suggests that residue packing, depth and conservation are crucial parameters for the understanding of
evolutionary constraints in protein structure and have potential applications in predicting the impact of muta-
tions on protein stability and interactions. While residue depth is well correlated with residue conservation, the
residue packing density offers a greater potential to differentiate between disease and non-disease mutations.
We are now investigating the impact of water molecules that are bound in the interior and are completely
solvent-inaccessible in order to further refine the calculation of packing densities.
In many cases multiple mutations have impacts on resistance, some increasing the resistance and others compen-
sating for the original mutation. One approach is to use SDM or mCSM (see above) to estimate whether a single
mutation is stabilising or destabilising. We model this mutation into the protein and treat it as the wild-type. We
can then explore whether further mutations are likely to be stabilising, compensating for the first or lead to further
instability. In future, we intend to look at the impacts of multiple mutations using machine-learning methods.
Future challenges and applications of structure-guided
drug discovery
Structure-guided approaches have demonstrated clearly that they can contribute to many aspects of early drug
discovery, both computational and experimental. Structure can also inform our understanding of impacts of
mutations in human genetic diseases and drug resistance in cancers and infectious disease. The Open Source
Figure 4. Residue conservation as a function of residue packing (A–C) and depth (D–F).
D1 corresponds to all residues with RSA > 7%. The remaining inaccessible residues were categorised into the D2 and D3. For the case of packing
(A–C), D2 and D3 corresponds to residue packing values ≤0.56 and >0.56, respectively. For depth (D–F), D2 and D3 corresponds to residue depth
values ≤6 and >6 Å, respectively. Residue conservation with packing and depth were analysed for residues grouped on the basis of polar, charged
and hydrophobic properties. Residue conservations were obtained from the substitution tables calculated using the ULLA program [58]. Ulla uses
structural alignment of protein families annotated by the program JOY, indicating the local conformation and side-chain environment [54] for the
purpose of calculating substitution tables.
308 © 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
Biochemical Society Transactions (2017) 45 303–311
DOI: 10.1042/BST20160422
Drug Discovery programme in India (http://www.osdd.net/about-us) has developed approaches using structural
information to identify current, off-licence drugs that might be repurposed for use against infectious diseases in
developing countries.
Our and others’ research on understanding the impacts of mutations in genetic disease has demonstrated
that mechanisms often involve interfacial disruptions and allosteric impacts on multiprotein assemblies and
more simple oligomeric protein functions. Here, the design of interfacial stabilisers offers an attractive way
forward that depends on a detailed knowledge of protein structure. Other approaches to combatting resistance
include the use of peptidic inhibitors, which have more intrinsic flexibility and can often adopt other confor-
mations to make alternative interactions with the mutant protein.
Our analysis of mechanisms of emergence of resistance in cancer and infectious disease and the methods for
predicting it have been equally dependent on structural insights on protein targets. In combating resistance, an
initial objective might be to design the candidate drug to interact only with residues used by the natural
ligands; this would increase the chance that mutations affect the viability of the tumour or infectious agent as
well as the drug. However, if it is necessary to find drug interactions beyond the interaction site of the natural
substrates and cofactors, in silico saturation mutagenesis can be used to inform the choice of ways to grow frag-
ments or redesign drugs, in such a way that they would less likely give rise to resistance mutations. In all these
ways structural biology appears to be a central component of future efforts in drug discovery!
Abbreviations
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Figure 5. Mapping of residue conservation along with (A) residue packing and (B) residue depth for disease-related mutations in AKU.
In (A) and (B), one of the protomers is shown as a ribbon diagram and the remaining five protomers are shown as a surface representation coloured
in yellow. The disease mutants are coloured based on residue conservation. The conservation score range between 1 and 9 with low (in red) and
high (in blue) score values corresponding to low and high conservation, respectively. In (A), the increasing thickness of the ribbon corresponds to
the increasing residue packing in the protomer. Similarly, in (B), the increasing thickness of the ribbon corresponds to the increasing residue depth
in the protomer. The colour gradient bar representing the residue conservation score is shown on top of the figure.
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